Published: Fri, March 10, 2017
Health Care | By Jeffery Armstrong

Barclays PLC Begins Coverage on AstraZeneca plc (AZN)


AstraZeneca PLC (LON:AZN) had its stock rating reiterated as "Buy" in a report released by analysts at Liberum Capital. Berenberg Bank raised shares of Intertek Group plc to a "buy" rating and lifted their target price for the stock from GBX 3,600 ($44.03) to GBX 4,000 ($48.92) in a research note on Thursday, January 19th.

Shares of AstraZeneca plc (NYSE:AZN) traded down 0.253% during trading on Tuesday, reaching $29.545. BlackRock Advisors LLC now owns 2,157,725 shares of the company's stock worth $70,902,000 after buying an additional 2,029,725 shares during the last quarter. The stock's market capitalization is GBX 55.53 billion.

Among 31 analysts covering AstraZeneca PLC (LON:AZN), 16 have Buy rating, 4 Sell and 11 Hold.

While looking at the Stock's Performance, AstraZeneca PLC now shows a Weekly Performance of 0.85%, where Monthly Performance is 11.04%, Quarterly performance is 18.57%, 6 Months performance is -6.13% and yearly performance percentage is 7.42%.

AstraZeneca plc (NYSE:AZN) last issued its quarterly earnings results on Thursday, February 2nd.

Taking look on per share earnings estimates, its next year first quarter current estimate trend for EPS was for $1.95 and on annual basis FY 2016 estimate trends at current was for $7.56 as compared to one month ago of $7.70, and for next year per share earnings estimates have $8.41. The company had revenue of $5.59 billion for the quarter, compared to analyst estimates of $5.43 billion.

In the trailing 12 months period, return on assets ratio of the Company was 5.50% and return on equity ratio was 24.90% while its return on investment ratio was 15.00%. During the same period in the previous year, the company posted $0.94 earnings per share. AstraZeneca plc has a 52-week low of GBX 3,680.00 and a 52-week high of GBX 5,505.00.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of worldwide copyright and trademark legislation. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/03/07/barclays-plc-begins-coverage-on-astrazeneca-plc-azn.html.

The firm also recently announced a semiannual dividend, which will be paid on Monday, March 20th. Stockholders of record on Thursday, May 18th will be paid a GBX 43 ($0.53) dividend. This represents a yield of 6.81%. The ex-dividend date of this dividend is Wednesday, February 15th.

Large investors have recently made changes to their positions in the company. BlackRock Investment Management LLC boosted its stake in AstraZeneca plc by 73.2% in the second quarter. Boyer & Corporon Wealth Management LLC now owns 28,222 shares of the company's stock valued at $852,000 after buying an additional 434 shares during the period. Ltd. now owns 220,574 shares of the company's stock worth $7,248,000 after buying an additional 6,818 shares in the last quarter. Primecap Management Co. CA boosted its stake in AstraZeneca plc by 17.4% in the second quarter. Capital International Investors now owns 20,473,479 shares of the company's stock worth $618,094,000 after buying an additional 3,705,199 shares during the last quarter.

BioPharmX Corporation is a specialty pharmaceutical company.

Like this: